Spreadsheet: 1cbde627-55f1-47bc-903f-17b591c616f1
Sheet: tab03_byage

 | Estimated Vaccination Coverage With Selected Vaccines Among Adolescents Aged 13-17* Years by Age at Interview - National Immunization Survey-Teen, 2013
Vaccines | Age at Interview (years)
 | 13 | 14 | 15 | 16 | 17 |  | 2013
 | (n = 3,937) | (n = 3,961 ) | (n = 3,892) | (n = 3,825) | (n = 3,584) |  | (n = 18,264)
 | % (95% CI)† | % (95% CI) | % (95% CI) | % (95% CI) | % (95% CI) |  | % (95% CI)
[NAME] 2 doses MMR§ | 92.6(±1.4) | 93.1(±1.4) | 91.4(±2.1) | 92.0(±1.6) | 89.7(±2.3) |  | 91.8(±0.8)
[NAME] 3 doses Hepatitis B | 94.7(±1.3) | 94.0(±1.3) | 92.5(±1.9) | 93.1(±1.5) | 91.4(±2.2) |  | 93.2(±0.7)
Varicella
History of varicella disease¶ | 15.6(±2.1) | 19.5(±2.4) | 25.1(±2.5) | 30.6(±2.8) | 37.1(±3.0) |  | 25.4(±1.2)
[NAME] 1 dose vaccine if had no history of disease | 97.4(±0.8) | 95.4(±1.6) | 94.6(±2.0) | 94.0(±1.9) | 91.9(±3.3) |  | 94.9(±0.9)
[NAME] 2 doses vaccine if had no history of disease | 83.1(±2.2) | 80.2(±2.5) | 78.7(±3.0) | 76.6(±3.1) | 71.6(±4.0) |  | 78.5(±1.3)
History of disease or received [NAME] 2 doses varicella vaccination | 85.7(±1.9) | 84.1(±2.1) | 84.0(±2.3) | 83.7(±2.3) | 82.2(±2.8) |  | 84.0(±1.0)
Td or Tdap**
[NAME] 1 dose Td or [NAME] | 88.9(±1.8) | 90.2(±1.9) | 90.3(±1.6) | 88.3(±2.0) | 87.3(±2.6) |  | 89.1(±0.9)
[NAME] 1 dose [NAME] | 87.2(±1.9) | 87.0(±2.1) | 88.4(±1.7) | 84.3(±2.1) | 83.0(±2.7) |  | 86.0(±0.9)
≥1 dose [NAME] | 76.1(±2.4) | 78.2(±2.3) | 80.0(±2.3) | 77.8(±2.5) | 76.7(±2.9) |  | 77.8(±1.1)
HPV§§
FEMALE
[NAME] 1 dose | 50.6(±4.1) | 55.1(±4.2) | 58.8(±4.3) | 60.0(±4.5) | 62.3(±4.5) |  | 57.3(±1.9)
[NAME] 2 doses | 39.2(±4.2) | 43.3(±4.2) | 48.7(±4.5) | 51.1(±4.6) | 56.8(±4.5) |  | 47.7(±2.0)
[NAME] 3 doses | 25.8(±3.8) | 32.1(±3.9) | 39.4(±4.6) | 43.1(±4.5) | 48.2(±4.5) |  | 37.6(±1.9)
MALE
[NAME] 1 dose | 33.5(±4.5) | 35.1(±4.4) | 36.2(±4.1) | 35.9(±4.0) | 32.1(±4.1) |  | 34.6(±1.9)
[NAME] 2 doses | 23.4(±4.3) | 24.3(±4.0) | 23.8(±3.8) | 23.2(±3.7) | 22.9(±3.5) |  | 23.5(±1.7)
[NAME] 3 doses | 11.7(±2.7) | 13.6(±3.3) | 15.3(±3.5) | 13.7(±3.1) | 15.1(±3.0) |  | 13.9(±1.4)
HPV 3 dose series completion¶¶
Females | 56.1(±6.7) | 64.7(±5.7) | 72.1(±5.0) | 75.9(±5.6) | 79.5(±4.6) |  | 70.4(±2.5)
Males | 41.6(±9.4) | 47.1(±9.3) | 51.0(±8.7) | 48.8(±8.2) | 53.4(±8.5) |  | 48.3(±4.0)
 | * Adolescents in the 2013 NIS-Teen were born January 1995 through February 2001. Vaccination coverage estimates include only adolescents who had adequately complete provider-reported immunization records. National estimates do not include adolescents living in the U.S. Virgin Islands (n=332) and Guam (n=363).
 | †Estimate presented as point estimate (%) ± 95% confidence interval (CI).
 | § ≥2 doses of measles, mumps, and rubella (MMR) vaccine.
 | ¶  By parent/guardian report or provider records.
 | ** ≥1dose of tetanus and diptheria toxoid vaccine (Td), tetanus toxoid, reduced diptheria toxid, and acellular pertussis ([NAME]), or tetanus-unknown type vaccine, since age 10 years.
 | ††  ≥1 dose of meningococcal conjugate vaccine or meningococcal-unknown type (MenACWY) vaccine.
 | §§  ≥1dose of human papillomavirus (HPV) vaccine, either quadrivalent or bivalent. Percentages reported among females (n=8,710) and males (n=9,554). Some adolescents may have received more than the three recommended HPV doses.
 | ¶¶ Percent of females or males who received three doses among those who had at least one human papillomavirus (HPV) vaccine dose with at least 24 weeks between the first dose and the interview date.